Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Jun 23:11:1239478.
doi: 10.3389/fcell.2023.1239478. eCollection 2023.

Editorial: Molecular drivers of prostate cancer pathogenesis and therapy resistance

Girijesh Kumar Patel  1 , Santosh Kumar Verma  2 , Shagun Misra  3 , Gyan Chand  4 , Ram Nawal Rao  5
Affiliations
Editorial

Editorial: Molecular drivers of prostate cancer pathogenesis and therapy resistance

Girijesh Kumar Patel et al. Front Cell Dev Biol. .
No abstract available

Keywords: cancer stem cell; castrate-resistant prostate cancer; metastasis; neuroendocrine differentiation; recurrence; therapy resistance.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Comment on

  • Editorial on the Research Topic Molecular drivers of prostate cancer pathogenesis and therapy resistance

Similar articles

See all similar articles

References

    1. Antonarakis E. S., Lu C., Wang H., Luber B., Nakazawa M., Roeser J. C., et al. (2014). AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N. Engl. J. Med. 371 (11), 1028–1038. 10.1056/NEJMoa1315815 - DOI - PMC - PubMed
    1. Aytes A., Giacobbe A., Mitrofanova A., Ruggero K., Cyrta J., Arriaga J., et al. (2018). NSD2 is a conserved driver of metastatic prostate cancer progression. Nat. Commun. 9 (1), 5201. 10.1038/s41467-018-07511-4 - DOI - PMC - PubMed
    1. Beltran H., Rickman D. S., Park K., Chae S. S., Sboner A., MacDonald T. Y., et al. (2011). Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 1 (6), 487–495. 10.1158/2159-8290.CD-11-0130 - DOI - PMC - PubMed
    1. Dardenne E., Beltran H., Benelli M., Gayvert K., Berger A., Puca L., et al. (2016). N-myc induces an EZH2-mediated transcriptional program driving neuroendocrine prostate cancer. Cancer Cell 30 (4), 563–577. 10.1016/j.ccell.2016.09.005 - DOI - PMC - PubMed
    1. David M. K., Leslie S. W. (2023). Prostate Specific Antigen, StatPearls, Treasure Island (FL) ineligible companies. Disclosure: Stephen Leslie declares no relevant financial relationships with ineligible companies.

Publication types

LinkOut - more resources